Patents by Inventor Francesca Viti

Francesca Viti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
    Publication number: 20190367480
    Abstract: The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 5, 2019
    Inventors: Daan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti
  • Alkylamido Compounds and Uses Thereof
    Publication number: 20190269637
    Abstract: Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.
    Type: Application
    Filed: October 2, 2018
    Publication date: September 5, 2019
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods of treating hair related conditions
    Patent number: 10398667
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 3, 2019
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Antisense compositions and methods of making and using same
    Patent number: 10272047
    Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: April 30, 2019
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods of Treating Colorectal Cancer
    Publication number: 20190100758
    Abstract: Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 4, 2019
    Inventors: Giovanni Monteleone, Salvatore Bellinvia, Francesca Viti
  • Heterocycles capable of modulating T-cell responses, and methods of using same
    Patent number: 10208017
    Abstract: The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: February 19, 2019
    Assignee: Nogra Pharma Limited
    Inventors: Daan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti
  • METHODS OF TREATING LACTOSE INTOLERANCE
    Publication number: 20190046490
    Abstract: Disclosed herein in part are methods for treating lactose intolerance, including administering fatty acid compounds that modulate PPAR? receptors.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 14, 2019
    Inventors: Marie McNulty, Francesca Viti, Salvatore Bellinvia
  • Methods of Treating Hair Related Conditions
    Publication number: 20180369178
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 27, 2018
    Applicants: Nogra Pharma Limited, Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • IL-34 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USING SAME
    Publication number: 20180338992
    Abstract: Disclosed herein are antisense oligonucleotide sequences against IL-34 and methods for treating inflammatory diseases, such as inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an IL-34 antisense oligonucleotide useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed IL-34 antisense oligonucleotide to be used in treating inflammatory diseases and/or fibrosis.
    Type: Application
    Filed: November 25, 2016
    Publication date: November 29, 2018
    Applicant: Nogra Pharma Limited
    Inventors: Marie McNulty, Francesca Viti, Salvatore Bellinvia
  • Alkylamido compounds and uses thereof
    Patent number: 10137101
    Abstract: Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 27, 2018
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods of treating colorectal cancer
    Patent number: 10006029
    Abstract: Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 26, 2018
    Assignee: Nogra Pharma Limited
    Inventors: Giovanni Monteleone, Salvatore Bellinvia, Francesca Viti
  • Antisense compositions and methods of making and using same
    Patent number: 9982264
    Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 29, 2018
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods for Monitoring Responsiveness to Anti-SMAD7 Therapy
    Publication number: 20180128829
    Abstract: Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemsistry, and/or ELISA.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 10, 2018
    Inventors: Giovanni Monteleone, Francesca Viti, Salvatore Bellinvia
  • METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISORDERS
    Publication number: 20180113139
    Abstract: Disclosed herein are methods for diagnosing and/or treating inflammatory bowel diseases associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an inhibitor of IL-34 useful for treating inflammatory bowel diseases and manufacture of medicaments containing an inhibitor of IL-34 to be used in treating inflammatory bowel disease.
    Type: Application
    Filed: July 28, 2015
    Publication date: April 26, 2018
    Inventors: Salvatore Bellinvia, Francesca Viti
  • Methods for preventing or reducing colon carcinogenesis
    Patent number: 9913817
    Abstract: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 13, 2018
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • METHODS OF TREATING FIBROSIS
    Publication number: 20180065921
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Application
    Filed: May 12, 2017
    Publication date: March 8, 2018
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • METHODS OF TREATING LACTOSE INTOLERANCE
    Publication number: 20180064667
    Abstract: Disclosed herein are methods for treating lactose intolerance, including compounds that may be specific or modulate PPAR? receptors.
    Type: Application
    Filed: May 12, 2017
    Publication date: March 8, 2018
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods of treating hair related conditions
    Patent number: 9901557
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: February 27, 2018
    Assignee: NOGRA PHARMA LIMITED
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Methods of monitoring responsiveness to anti-SMAD7 therapy
    Patent number: 9791442
    Abstract: Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 17, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Giovanni Monteleone, Francesca Viti, Salvatore Bellinvia
  • BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
    Publication number: 20170183313
    Abstract: The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T cell responses.
    Type: Application
    Filed: December 14, 2016
    Publication date: June 29, 2017
    Inventors: Daan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti